Telephone
61.2.8964.7401
Address
Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000
Description
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.1
Trade Value (12mth)
AU$62,928.00
1 week
-13.33%
1 month
-47.3%
YTD
88.29%
1 year
64.75%
All time high
0.84
EPS 3 yr Growth
114.30%
EBITDA Margin
N/A
Operating Cashflow
-$17m
Free Cash Flow Return
-101.60%
ROIC
-78.20%
Interest Coverage
-937.40
Quick Ratio
13.90
Shares on Issue (Fully Dilluted)
2683m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 September 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
30 August 24 |
ACW Appendix 4E and 2024 Annual Report
×
ACW Appendix 4E and 2024 Annual Report |
30 August 24 |
ACW FY2024 results, advancing into late-stage trials
×
ACW FY2024 results, advancing into late-stage trials |
30 August 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 August 24 |
Appendix 4G
×
Appendix 4G |
29 August 24 |
ACW updated positive depression trial results presentation
×
ACW updated positive depression trial results presentation |
26 August 24 |
ACW updated depression trial results and implications
×
ACW updated depression trial results and implications |
13 August 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
12 August 24 |
ACW XanaCIDD phase 2a trial topline results
×
ACW XanaCIDD phase 2a trial topline results |
08 August 24 |
Trading Halt
×
Trading Halt |
31 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
29 July 24 |
ACW CMO presents academic poster at AAIC in Philadelphia
×
ACW CMO presents academic poster at AAIC in Philadelphia |
25 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
24 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
22 July 24 |
ACW June 2024 quarterly activity report & Appendix 4C
×
ACW June 2024 quarterly activity report & Appendix 4C |
19 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
18 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
17 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
10 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
09 July 24 |
Results of Meeting
×
Results of Meeting |
05 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
04 July 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
02 July 24 |
ACW XanaCIDD depression trial results expected early August
×
ACW XanaCIDD depression trial results expected early August |
26 June 24 |
Positive Xanamem biomarker trial published in Jnl Alz Dis
×
Positive Xanamem biomarker trial published in Jnl Alz Dis |
17 June 24 |
Application for quotation of securities - ACW
×
Application for quotation of securities - ACW |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.